Analyst Ratings for RAPT Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 analysts have published their opinion on RAPT Therapeutics (NASDAQ:RAPT) stock. The company has an average price target of $35.6, an increase of 6.27% from the previous average price target of $33.50. The majority of the ratings are bullish.
September 14, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have a bullish outlook on RAPT Therapeutics, with an average price target of $35.6, indicating potential upside.
The bullish ratings from analysts suggest a positive outlook for RAPT Therapeutics. The increased average price target indicates potential upside, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100